Research Article

Tanshinone IIA Induces Apoptosis in Human Oral Cancer KB Cells through a Mitochondria-Dependent Pathway

Pao-Yu Tseng, 1 Wei-Cheng Lu, 2 Ming-Ju Hsieh, 2,3,4 Su-Yu Chien, 5,6,7 and Mu-Kuan Chen 1,3

1 Department of Otorhinolaryngology, Head and Neck Surgery, Changhua Christian Hospital, No. 135 Nanxiao Street, Changhua 500, Taiwan
2 Cancer Research Center, Changhua Christian Hospital, Changhua 500, Taiwan
3 Institute of Medicine, Chung Shan Medical University, Taichung 500, Taiwan
4 School of Optometry, Chung Shan Medical University, Taichung 402, Taiwan
5 Department of Pharmacy, Changhua Christian Hospital, No. 135 Nanxiao Street, Changhua 500, Taiwan
6 School of Pharmacy, China Medical University, Taichung 404, Taiwan
7 College of Health Sciences, Chang Jung Christian University, Tainan 711, Taiwan

Correspondence should be addressed to Su-Yu Chien; 2655@cch.org.tw and Mu-Kuan Chen; 53780@cch.org.tw

Received 26 February 2014; Accepted 12 April 2014; Published 13 May 2014

Academic Editor: Tsung-Lin Yang

Copyright © 2014 Pao-Yu Tseng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Tanshinone IIA (Tan IIA), an active phytochemical in the dried root of Salvia miltiorrhiza Bunge, has shown an antiproliferative activity on various human cancer cell lines including nasopharyngeal carcinoma cells. However, the effects of Tan IIA on human oral cancer cells are still unknown. This study aimed to investigate the antiproliferative effects of Tan IIA on human oral cancer KB cells and explored the possible underlying mechanism. Treatment of KB cells with Tan IIA suppressed cell proliferation/viability and induced cell death in a dose-dependent manner through sulforhodamine B colorimetric assay. Observation of cell morphology revealed the involvement of apoptosis in the Tan IIA-induced growth inhibition on KB cells. Cell cycle analysis showed a cell cycle arrest in G2/M phase on Tan IIA-treated cells. The dissipation of mitochondrial membrane potential observed by flow cytometry and the expression of activated caspases with the cleaved poly (ADP-ribose) polymerase under immunoblotting analysis indicated that Tan IIA-induced apoptosis in KB cells was mediated through the mitochondria-dependent caspase pathway. These observations suggested that Tan IIA could be a potential anticancer agent for oral cancer.

1. Introduction

The incidence of oral cancer increases annually with the epidemiology of oral and oropharyngeal cancer, grouped together, as the sixth most common cancer worldwide [1]. It is estimated that about 275000–300000 people will be diagnosed with oral cancer annually [1, 2]. The management of oral cancer is complex and challenging. The majority of treatment includes surgery alone for very early stage patient, surgery with adjuvant concurrent chemoradiotherapy or radiotherapy alone, neoadjuvant chemotherapy followed by surgery and adjuvant concurrent chemoradiotherapy in locally advanced disease, and chemoradiotherapy alone in certain status like inoperative cases [3–8].

With many choices of treatment available, the role of chemotherapy is moving toward a more prominent position. The compounds extracted from the natural sources have been introduced into the chemotherapy of head and neck cancers. Taxanes including paclitaxel, the ingredient in the Pacific yew tree, and docetaxel, an extract of European yew tree, are cytotoxic agents that interfere with the microtubule structure and cause the pause of cell division [9, 10]. Paclitaxel and docetaxel have been used as chemotherapy agents to treat squamous cell carcinoma of the head and neck in selected patients with survival benefits in clinical practice [11–13].

Danshen, the dried root of Salvia miltiorrhiza Bunge, has been used for the treatment of coronary artery diseases and cerebrovascular diseases in traditional Chinese
mechanism. Tanshinone IIA (Tan IIA), a diterpene quinonic compound from the extractable ingredient of Danshen, has shown its ability to protect from H₂O₂-induced cell death in cardiac myocytes and macrophage [14, 15]. In addition, Tan IIA was reported to have the growth inhibitory effects and induced apoptosis on various cancer cell lines [16–19]. These studies indicated that Tan IIA could induce cell death through activation of selective members in caspase family and trigger the mitotic arrested cells to enter apoptosis [16, 17]. Yang et al. also pointed out that Tan IIA caused the release of cytochrome c, the loss of mitochondrial membrane potential, and subsequently the apoptosis of the EAhy926 human endothelial cells [19]. However, the effects of Tan IIA on human oral cancer cells are still unclear. This study was designed to investigate the cytotoxic effects of Tan IIA on human KB cells and discussed the possible underlying mechanism. Our data showed that Tan IIA may have the potential to become a novel agent of chemotherapy for oral cancer.

2. Materials and Methods

2.1. Reagents. Tanshinone IIA (Tan IIA) was purchased from Herbacin Co., Ltd. (Shenyang, China) and dissolved in pure grade dimethyl sulfoxide (DMSO). Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum, penicillin, streptomycin, and 3, 3′-dihexyloxacarbocyanine iodide (DiOC₆) were purchased from Gibco/Invitrogen (Carlsbad, CA, USA). The protein assay kit was obtained from Bio-Rad (Hercules, CA, USA). Antibodies to caspase-3, caspase-9, poly-(ADP-ribose) polymerase (PARP), and β-actin were purchased from Cell Signaling Technology, Inc. (Beverley, MA). PVDF membrane and chemiluminescent substrates for horseradish peroxidase (HRP) were purchased from Millipore (Bedford, MA, USA). Unless otherwise indicated, all other chemicals employed in this study were purchased from Sigma Chemical Co. (St. Louis, MO, USA).

2.2. Cell Culture. The human oral squamous carcinoma KB cells were from ATCC (Manassas, VA, USA). The cells were cultured in DMEM supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 μg/mL streptomycin at 37°C in one atmosphere with 5% CO₂.

2.3. Cytotoxicity Assay. KB cells (8 × 10⁴ cells/well) were seeded in 96-well plate and grew overnight. Various concentrations of Tan IIA (0, 5, 10, 20 and 25 μg/mL) were added and incubated for 24, 48, and 72 hours. The cell viability was determined by sulforhodamine B (SRB) colorimetric assay at different time periods.

For SRB colorimetric assay, 10% wt/vol trichloroacetic acid was added to each well and the cells were then washed by tap water after 60 minutes. After dehydration, the plates were incubated in 0.4% SRB and then washed by 1% acetic acid after 15 minutes. Subsequently, 10 mM Tris buffer (pH 10.5) was added to dissolve precipitates. Finally, the optical density at 492 nm was measured to determine the cell viability.

2.4. Determination of Apoptosis and Morphologic Changes. KB cells treated with different concentrations of Tan IIA (0, 5, 10, and 20 μg/mL) were incubated at indicated time points (24 and 48 hours), the cells were fixed with 4% paraformaldehyde for 15 minutes at room temperature and kept incubating overnight at 4°C. Then, the plates were washed twice with phosphate-buffered saline (PBS) and nuclei were stained with 100 ng/mL Hoechst for 15 minutes in the dark. Following three times of tap water washing, the cells were examined under a fluorescence microscope. Cells with rough surface and dark stained nuclei with fragmented chromosome were considered as apoptotic cells. The apoptotic cells were counted for each sample.

2.5. DNA Cell Cycle Analysis. For the cell cycle analysis, the cellular DNA content was detected by flow cytometry. KB cells were plated in 6-well plates and incubated with Tan IIA (0, 5, and 10 μg/mL) for 24 and 48 hours. The cells were harvested by centrifugation, washed with PBS, and fixed in 70% ethanol at −20°C overnight. Then, the cells were washed twice by ice-cold PBS and incubated in PBS containing 4 μg/mL of propidium iodide, 0.1 mg/mL RNase A, and 0.1% Triton X-100 at room temperature for 1 hour in the dark. Finally, the cell cycle was analyzed with flow cytometry (Beckman FC500, San Diego, CA, USA).

2.6. Measurement of Mitochondrial Membrane Potential. KB cells were plated in 12-well plates and treated with different concentrations of Tan IIA (0, 5, and 10 μg/mL) for 24 hours. The harvested cells were washed twice with PBS, resuspended in 10 μM of 3,3′-dihexyloxacarbocyanine iodide (DiOC₆), and incubated at 37°C for 30 minutes. Subsequently, the cells were analyzed with flow cytometry (Beckman FC500, San Diego, CA, USA).

2.7. Western Blot Analysis for PARP and Caspase Activity. After incubation with Tanshinone IIA (0, 5, 10 and 20 μg/mL) for 24 hours, KB cells were harvested and washed with cold PBS. Then, cell pellets were lysed in ice-cold RIPA buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na₂ EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na₃VO₄, and 1 μg/mL leupeptin for 5 minutes. The supernatants were collected by centrifugation at 11,752 g for 10 minutes at 4°C. The protein concentration was measured using the Bradford protein assay (Bio-Rad, Hercules, CA, USA). Proteins were electrophoretically separated on 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred to PVDF membrane. Membranes were supplemented with 5% nonfat dry milk and PBS containing 0.1% Tween-20 at room temperature for 1 hour. Then, membranes were incubated with diluted primary antibody against caspase-3, caspase-9, PARP, and β-actin at 4°C with gentle shaking overnight. After washing with PBST for three times, membranes were incubated with the appropriate horseradish peroxidase-conjugated secondary antibody at room temperature for 1 hour. Rewashing with
3. Results

3.1. Tanshinone IIA Inhibited Cell Growth and Caused Apoptosis of Oral KB Cells. To examine the cytotoxicity of Tan IIA on KB cells, the cells were evaluated by SRB colorimetric assay. The dose-dependent growth inhibitory effects were observed (Figure 1). The survival rates of 94.0%, 39.5%, 33.1%, and 23.0%, respectively, compared with that in non-Tan IIA-treated cells (Figure 3). Moreover, the appearance of sub-G1 population indicated a proportion of apoptotic cell. The results suggested that Tan IIA-induced cell death might be involved in the induction of G2/M phase arrest and apoptosis.

3.2. Tanshinone IIA Arrested KB Cells in G2/M Phase. To evaluate the effect of Tan IIA on cell cycle progression, the cell cycle distribution was determined through flow cytometry analysis. After treatment with 10 μg/mL of Tan IIA for 24 and 48 hours, there was an accumulation of cells in G2/M phase, while the cells in G0/G1 phase decreased compared with that in non-Tan IIA-treated cells (Figure 3). Moreover, the appearance of sub-G1 population indicated a proportion of apoptotic cell. The results suggested that Tan IIA-induced cell death might be involved in the induction of G2/M phase arrest and apoptosis.

3.3. Tanshinone IIA Induced the Loss of Mitochondrial Membrane Potential. The loss of mitochondrial membrane potential (ΔΨm) has been regarded as one of the early events in the apoptotic pathway, which can trigger the release of cytochrome c and other apoptogenic molecules after induction by various stimuli [20, 21]. To detect the change of the mitochondrial membrane potential, we used a mitochondria-specific and voltage-dependent dye, DiOC6(3), to stain the cells and then analyzed them through flow cytometry. As shown in Figure 4, KB cells treated with 10 μg/mL of Tan IIA for 24 hours underwent the disruption of the mitochondrial membrane potential. Around 20% of the treated cells lost their mitochondrial membrane potential.

3.4. Tanshinone IIA Induced the Activation of Caspase-3, Caspase-9, and PARP. It is known that the apoptotic intrinsic pathway is initiated by intracellular stress, which dissipates transmembrane potential of mitochondrial membrane and results in the release of proapoptotic factors, including cytochrome c [20, 21]. The increased level of cytochrome c in the cytosol results in the initiation of caspase-9 and caspase-3 and the subsequent activation of PARP and induces the morphological changes of the dying cell [20–26]. In this signaling pathway, the specific PARP, a biochemical characteristic of apoptosis, mainly depends on the activation of caspase-3 [27]. In our study, western blot analysis was used to determine the effect of Tan IIA on caspase proteins and PARP. After exposure to different concentrations of Tan IIA (0, 5, 10, and 20 μg/mL) for 24 hours, cellular proteins were lysed and immunoblotting was performed. Figure 5 showed the activated subunits of caspase-9 with the decreased expression of procaspase-3 in Tan 20 group; a 116 kDa PARP was also cleaved to an 89 kDa fragment. The results suggested that Tan IIA-induced KB cell death was involved in the activation of caspase-3 and caspase-9 and the cleavage of PARP.
Figure 2: Assessment of nuclear morphological changes of KB cells exposed to Tan IIA. KB cells were treated with various concentrations of Tan IIA (0, 5, 10, and 20 μg/mL) for different time periods. (a) After 24 hours, cells stained with Hoechst and exhibiting shrunk, condensed nuclei with fragmented chromosomes under fluorescent microscope were identified as apoptotic cells. (b) Apoptotic rates were calculated. The points are the mean ± SD of 2 independent experiments. * indicates $P < 0.05$.

4. Discussion

Tanshinone IIA (Tan IIA) is one major component of the dried root of Salvia miltiorrhiza Bunge. It acts as two faces in the biological and pharmacological effects. Some studies showed that Tan IIA is correlated with protection from cell death in cardiac myocytes and macrophage [14, 15]. However, others reported that Tan IIA has cytotoxic effects on several cancer cells [16–19]. The effects of Tan IIA on human oral cancer cells still remain unknown. The goal of this study is to investigate whether Tan IIA shows the anticancer effects on human oral cancer KB cells and to explore the possible underlying mechanism. Our findings indicate that Tan IIA inhibits cell proliferation, stops cell cycle progression, and induces apoptosis through the intrinsic mitochondrial pathway.

Apoptosis, one type of programmed cell death, is a well-defined self-suicide process counteracting tumor growth. Many chemotherapy drugs produce antitumor effects by triggering the apoptosis through a variety of molecular mechanisms [28]. As the natural phytochemicals have been increasingly employed as chemotherapy agents, we examined the cytotoxic effect of Tan IIA on KB cells and assessed the possible application of this ancient herbal medicine as a novel agent for treatment of oral cancer. In the present study, we demonstrated a naturally extracted Tan IIA inhibited the proliferation and viability of KB cancer cells in a dose-dependent manner using SRB colorimetric assay. More than 90% of cells were killed after administration with 25 μg/mL of Tan IIA for 72 hours (Figure 1). Like studies mentioned above, Tan IIA did possess antiproliferative effects on human cancer cells. Furthermore, the cellular morphology was observed using Hoechst staining; those with shrunk and condensed fragmented chromosomes were identified as apoptotic cells (Figure 2(a)). Significant apoptosis developed when KB cells were treated with Tan 10 for 48 hours or Tan 20 for 24 and 48 hours (Figure 2(b)). Our results confirmed the involvement of apoptosis in response to Tan IIA in a dose-dependent manner.

Normal cell cycle progression is critical in regulating the cell proliferation and cell division. A dysregulation of the cell cycle that makes the cells undergo uncontrolled cell growth...
can result in the development of cancer. There are now more anticancer drugs that abrogate the cell cycle checkpoints and make the apoptosis develop [29, 30]. Thus, to target the errors of cell cycle regulation in cancer cells is considered a potential strategy for control of tumor growth. Previous studies showed that Tan IIA could arrest the nasopharyngeal carcinoma cell line (CNE-1) and human hepatocellular carcinoma cells (SMMC-7721) in G_0/G_1 phase, while other studies reported that human erythroleukemic cell line (K562) and HeLa cells were arrested in G_2/M phase [16, 17, 31, 32]. When the cell cycle is arrested, there comes an opportunity for cells to undergo either a repairing mechanism or the apoptotic cascade. Prolonged mitotic arrest induced by microtubule-interfering agents such as taxol and vincristine had been proved to make cells enter apoptosis [33, 34]. Zhou et al. had found that Tan IIA arrested HeLa cells in mitosis through disrupting the mitotic spindle and triggered the apoptosis [17]. Our data indicated that Tan IIA caused the decrease of KB cells in G_0/G_1 phase, an accumulation in G_2/M phase and an appearance in sub-G_1 proportion (Figure 3). Thus,
treatment of KB cells with Tan IIA induced G2/M phase arrest of cell cycle and the apoptosis indicating that Tan IIA might arrest cell cycle progression and lead to apoptosis.

Apoptotic signaling processes tightly regulated by many antiapoptotic and proapoptotic molecules have been divided into extrinsic and intrinsic pathways. In the intrinsic mitochondrial apoptotic signaling, Bcl-2 has been identified as an apoptotic inhibitor and Bax protein inhibits the function of bcl-2. The apoptotic proteins, Bak and Bax, are key components that initiate mitochondrial dysfunction; an increased Bax/Bcl-2 ratio disrupts the mitochondrial membrane potential [35–37]. The loss of mitochondrial membrane potential is one of the characteristic biochemical changes in apoptosis. Yang et al. pointed out that Tan IIA caused the decrease in mitochondrial membrane potential of the EAhy926 human endothelial cells [19]. We observed that Tan IIA treatment led to the dissipation of mitochondrial membrane potential in partial KB cancer cells (Figure 4). Thus, a mitochondrial response was involved in the Tan II A-induced apoptotic pathway of KB cancer cells. The loss of mitochondrial membrane potential results in the release of cytochrome c and other apoptogenic proteins from the mitochondria to cytosol. Consequently, the interaction between cytochrome c, apoptosis protease-activating factor 1, and ATP/dATP forms the apoptosome which activates caspase-9. The activation of caspase-9 causes the cleavage of caspase-3, a critical executioner of apoptosis. Subsequently the activated caspase-3 cleaves the substrates including PARP, ultimately leading to apoptosis [20–27]. Therefore, we evaluated the effect of Tan IIA on caspase proteins and PARP in KB cancer cells. Western blot analysis showed that Tan IIA treatment resulted in the activation of caspase-9, the triggering of caspase-3, and the cleavage of PARP in the KB cancer cells (Figure 5). Several studies also indicated that caspase-9, caspase-3, and PARP were associated with the Tan II A-induced apoptosis on the cancer cell lines [16, 17, 19]. Taken together, Tan IIA treatment led to the initiation of the intrinsic mitochondrial pathway and the activation of downstream caspase-3 in apoptosis of human oral cancer KB cells.

5. Conclusion

In conclusion, our study shows that Tan IIA suppresses the cell growth, arrests cells in G2/M phase, and induces the apoptotic cell death of human oral cancer KB cells. In addition, we find that Tan IIA induces the apoptosis of KB cells through mitochondrial-dependent pathway in which the loss of mitochondrial membrane potential and the activation of caspase-9 and caspase-3 are involved, though other routes may be associated with the apoptotic events and need further investigation. Data obtained from our study indicate that Tan IIA could be a potential anticancer agent for oral cancer.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgment

This research was financially supported by Changhua Christian Hospital Research grant.

References

[1] S. Warnakulasuriya, “Global epidemiology of oral and oropharyngeal cancer,” Oral Oncology, vol. 45, no. 4-5, pp. 309–316, 2009.
[2] A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA: A Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010.
[3] D. J. Adelstein, Y. Li, G. L. Adams et al., “An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer,” Journal of Clinical Oncology, vol. 21, no. 1, pp. 92–98, 2003.
[4] A. Psyrris, M. Kwong, S. DiStasio et al., “Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term
follow-up,” Journal of Clinical Oncology, vol. 22, no. 15, pp. 3061–3069, 2004.

[5] J. Rinehart, T. Ruff, A. Cheung et al., “Neoadjuvant and concomitant chemotherapy and radiation therapy in patients with advanced head and neck carcinoma,” Otolaryngology—Head and Neck Surgery, vol. 132, no. 1, pp. 69–74, 2005.

[6] C. M. Nutting, S. A. Bhide, and K. J. Harrington, “Treatment of head and neck cancer,” The New England Journal of Medicine, vol. 358, no. 10, pp. 1076–1077, 2008.

[7] J.-P. Pignon, A. L. Maitre, E. Maillard, and J. Bourhis, “Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients,” Radiotherapy and Oncology, vol. 92, no. 1, pp. 4–14, 2009.

[8] M. S. Kies, F. C. Holsinger, J. J. Lee et al., “Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 8–14, 2010.

[9] N. Kumar, “Taxol-induced polymerization of purified tubulin. Mechanism of action,” The Journal of Biological Chemistry, vol. 256, no. 20, pp. 10435–10441, 1981.

[10] S. J. Clarke and L. P. Rivory, “Clinical pharmacokinetics of M. Sairafianpour, J. Christensen, D. Steer et al., “Leishmanicidal, antiplasmodial, and cytotoxic activity of novel diterpenoid 1,2-quinones from Perovskia abrotanoides: new source of tanshinones,” Journal of Natural Products, vol. 64, no. 11, pp. 1398–1403, 2001.

[11] R. Hitt, A. López-Pousa, J. Martínez-Trufero et al., “Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8636–8645, 2005.

[12] M. R. Posner, D. M. Hershock, C. R. Blajman et al., “Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer,” The New England Journal of Medicine, vol. 357, no. 17, pp. 1705–1715, 2007.

[13] J. H. Lorch, O. Goloubeva, R. I. Haddad et al., “Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial,” The Lancet Oncology, vol. 12, no. 2, pp. 153–159, 2011.

[14] J. Fu, H. Huang, J. Liu, R. Pi, J. Chen, and P. Liu, “Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis,” European Journal of Pharmacology, vol. 568, no. 1–3, pp. 213–221, 2007.

[15] Y.-I. Li, G. Elmer, and R. C. LeBoeuf, “Tanshinone IIA reduces macrophage death induced by hydrogen peroxide by upregulating glutathione peroxidase,” Life Sciences, vol. 83, no. 15–16, pp. 557–562, 2008.

[16] H. J. Sung, S. M. Choi, Y. Yoon, and K. S. An, “Tanshinone IIA, an ingredient of Salvia miltiorrhiza BUNG, induces apoptosis in human leukemia cell lines through the activation of caspase-3,” Experimental and Molecular Medicine, vol. 31, no. 4, pp. 174–178, 1999.

[17] L. Zhou, W. K. Chan, N. Xu et al., “Tanshinone IIA, an isolated compound from Salvia miltiorrhiza Bunge, induces apoptosis in HeLa cells through mitotic arrest,” Life Sciences, vol. 83, no. 11-12, pp. 394–403, 2008.

[18] M. Sairafianpour, J. Christensen, D. Steer et al., “Leishmanicidal, antiplasmodial, and cytotoxic activity of novel diterpenoid 1,2-quinones from Perovskia abrotanoides: new source of tanshinones,” Journal of Natural Products, vol. 64, no. 11, pp. 1398–1403, 2001.

[19] L.-J. Yang, C.-J. Jeng, H.-N. Kung et al., “Tanshinone IIA isolated from Salvia miltiorrhiza elicits the cell death of human endothelial cells,” Journal of Biomedical Science, vol. 12, no. 2, pp. 347–361, 2005.

[20] G. Kroemer, L. Galluzzi, P. Vandenabeele et al., “Classification of cell death: recommendations of the nomenclature committee on cell death 2009,” Cell Death and Differentiation, vol. 16, no. 1, pp. 3–11, 2009.

[21] K. C. Zimmermann, C. Bonzon, and D. R. Green, “The machinery of programmed cell death,” Pharmacology & Therapeutics, vol. 92, no. 1, pp. 57–70, 2001.

[22] P. Li, D. Nijhawan, I. Budiardjo et al., “Cytochrome c and dATP-dependent formation of apaf-1/caspase-9 complex initiates an apoptotic protease cascade,” Cell, vol. 91, no. 4, pp. 479–489, 1997.

[23] D. R. Green and J. C. Reed, “Mitochondria and apoptosis,” Science, vol. 281, no. 5381, pp. 1309–1312, 1998.

[24] I. Budiardjo, H. Oliver, M. Lutter, X. Luo, and X. Wang, “Biochemical pathways of caspase activation during apoptosis,” Annual Review of Cell and Developmental Biology, vol. 15, pp. 269–290, 1999.

[25] X. Wang, “The expanding role of mitochondria in apoptosis,” Genes and Development, vol. 15, no. 22, pp. 2922–2933, 2001.

[26] M. Sebagh, C. Renvoizé, J. Hamelin, N. Riché, J. Bertoglio, and J. Bréard, “Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing,” Nature Cell Biology, vol. 3, no. 4, pp. 346–352, 2001.

[27] Y. O. Kussie, M. A. Thornberry, and J. B. Bode, “The ICE/ced-3 protease family,” Nature Immunology, vol. 1, no. 3, pp. 239–246, 2000.

[28] J. W. Wang, “Targeting of mitochondria by proapoptotic Bcl-2 family members,” Nature, vol. 401, pp. 92–96, 1999.

[29] D. W. Nicholson, A. Ali, N. A. Thornberry, and J. Bode, “Identification and inhibition of the ICE/ced-3 protease necessary for mammalian apoptosis,” Nature, vol. 376, no. 6535, pp. 37–43, 1995.

[30] W. Hu and J. J. Kavanagh, “Anticancer therapy targeting the apoptotic pathway,” The Lancet Oncology, vol. 4, no. 12, pp. 721–729, 2003.

[31] E. R. McDonald 3rd. and W. S. El-Deiry, “Cell cycle control as a basis for cancer drug development (review),” International Journal of Oncology, vol. 16, no. 5, pp. 871–886, 2000.

[32] G. K. Schwartz and M. A. Shah, “Targeting the cell cycle: a new approach to cancer therapy,” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9408–9421, 2005.

[33] S. Yuan, Y. Wang, X. Chen, Y. Song, and Y. Yang, “A study on apoptosis of nasopharyngeal carcinoma cell line induced by Tanshinone II A and its molecular mechanism,” Hua Xi Yi Ke Da Xue Xue Bao, vol. 33, no. 1, pp. 84–90, 2002.

[34] S.-L. Yuan, Y.-Q. Wei, X.-J. Wang, F. Xiao, S.-F. Li, and J. Zhang, “Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells,” World Journal of Gastroenterology, vol. 10, no. 14, pp. 2024–2028, 2004.

[35] K. N. Bhalla, “Microtubule-targeted anticancer agents and apoptosis,” Oncogene, vol. 22, no. 56, pp. 9075–9086, 2003.

[36] F. Mollinedo and C. Gajate, “Microtubules, microtubule-interfering agents and apoptosis,” Apoptosis, vol. 8, no. 5, pp. 413–450, 2003.

[37] B. C. Barnhart, J. C. Lee, E. C. Alappat, and M. E. Peter, “The death effector domain protein family,” Oncogene, vol. 22, no. 53, pp. 8634–8644, 2003.

[38] J. M. Adams and S. Cory, “Life-or-death decisions by the bcl-2 protein family,” Trends in Biochemical Sciences, vol. 26, no. 1, pp. 61–66, 2001.

[39] L. Scorrano, S. A. Oakes, J. T. Opferman et al., “BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis,” Science, vol. 300, no. 5616, pp. 135–139, 2003.